Brokerages Set Cellebrite DI Ltd. (NASDAQ:CLBT) PT at $23.43

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) have earned a consensus recommendation of "Buy" from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $23.43.

CLBT has been the subject of several analyst reports. Needham & Company LLC restated a "buy" rating and issued a $28.00 target price on shares of Cellebrite DI in a research report on Friday, February 14th. JPMorgan Chase & Co. lifted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Craig Hallum lifted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Finally, Lake Street Capital lifted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Mackenzie Financial Corp acquired a new position in shares of Cellebrite DI in the 4th quarter worth approximately $776,000. Public Employees Retirement System of Ohio lifted its position in shares of Cellebrite DI by 3.0% during the 4th quarter. Public Employees Retirement System of Ohio now owns 301,763 shares of the company's stock valued at $6,648,000 after acquiring an additional 8,648 shares during the period. Castleark Management LLC acquired a new position in shares of Cellebrite DI during the 4th quarter valued at $1,284,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Cellebrite DI by 32.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 148,132 shares of the company's stock valued at $3,263,000 after acquiring an additional 36,341 shares during the period. Finally, USS Investment Management Ltd acquired a new position in shares of Cellebrite DI during the 4th quarter valued at $706,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Remove Ads

Cellebrite DI Stock Up 0.3 %

Shares of NASDAQ:CLBT traded up $0.06 during midday trading on Wednesday, hitting $18.56. The stock had a trading volume of 3,566,309 shares, compared to its average volume of 2,188,033. The company's 50-day moving average price is $22.31 and its 200-day moving average price is $19.57. The company has a market capitalization of $3.82 billion, a P/E ratio of -13.35, a price-to-earnings-growth ratio of 4.27 and a beta of 1.47. Cellebrite DI has a fifty-two week low of $10.24 and a fifty-two week high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Research analysts expect that Cellebrite DI will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.